Adalimumab

Generic Name
Adalimumab
Brand Names
Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
Drug Type
Biotech
Chemical Formula
-
CAS Number
331731-18-1
Unique Ingredient Identifier
FYS6T7F842
Background

Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...

Indication

Adalimumab is indicated for the following conditions:

Adalimumab has also been used off-label to treat Pyoderma gangrenosum.

Associated Conditions
Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
Associated Therapies
-
Clinical Trials
Related News

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

First Posted Date
2017-04-07
Last Posted Date
2024-10-01
Lead Sponsor
AbbVie
Target Recruit Count
1705
Registration Number
NCT03104400
Locations
🇺🇸

Great Lakes Clinical Trials /ID# 163435, Chicago, Illinois, United States

🇨🇳

1st Aff Hosp of Bengbu Medical College /ID# 201021, Bengbu, Anhui, China

🇨🇳

The First Affiliated Hospital of Shantou University Medical College /ID# 203371, Shantou, Guangdong, China

and more 342 locations

Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation

First Posted Date
2017-04-04
Last Posted Date
2022-09-19
Lead Sponsor
Mario Negri Institute for Pharmacological Research
Target Recruit Count
208
Registration Number
NCT03100253
Locations
🇮🇹

Policlinico Sant'Orsola Malpighi, Bologna, Italy

🇮🇹

Azienda Consorziale Ospedaliera Policlinico, Bari, Italy

🇮🇹

Azienda Socio Sanitaria Territoriale - Papa Giovanni XXIII, Bergamo, Italy

and more 19 locations

Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD

Phase 4
Withdrawn
Conditions
Crohn Disease
Ulcerative Colitis
Interventions
Drug: Adalimumab
First Posted Date
2017-02-23
Last Posted Date
2020-01-18
Lead Sponsor
McMaster University
Registration Number
NCT03059849

Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab

First Posted Date
2016-11-15
Last Posted Date
2018-11-14
Lead Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Target Recruit Count
35
Registration Number
NCT02963402
Locations
🇪🇸

Insitut de Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis

First Posted Date
2016-10-11
Last Posted Date
2024-06-25
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
112
Registration Number
NCT02929251
Locations
🇫🇷

Hopital Pellegrin, Bordeaux, France

🇫🇷

Hopital Saint André - Médecine interne, Bordeaux, France

🇫🇷

HCL - Hôpital de la Croix Rousse - Ophtalmologie, Lyon, France

and more 24 locations

A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: DMB-3113
Drug: Adalimumab
First Posted Date
2016-10-07
Last Posted Date
2017-08-22
Lead Sponsor
Meiji Seika Pharma Co., Ltd.
Target Recruit Count
180
Registration Number
NCT02927353

Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers

First Posted Date
2016-09-23
Last Posted Date
2019-03-07
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
183
Registration Number
NCT02912247

Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa

Phase 3
Completed
Conditions
Hidradenitis Suppurativa
Interventions
Drug: adalimumab
First Posted Date
2016-09-19
Last Posted Date
2020-05-12
Lead Sponsor
AbbVie
Target Recruit Count
15
Registration Number
NCT02904902
Locations
🇯🇵

Fukuoka University Hospital /ID# 151350, Fukuoka, Japan

🇯🇵

Takagi Dermatological Clinic /ID# 151906, Obihiro, Hokkaido, Japan

🇯🇵

Kurume University Hospital /ID# 152579, Kurume-shi, Fukuoka, Japan

and more 5 locations

Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis

Phase 3
Completed
Conditions
AS
Interventions
Drug: IBI303
Drug: Adalimumab
First Posted Date
2016-09-08
Last Posted Date
2018-06-04
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
438
Registration Number
NCT02893254

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

First Posted Date
2016-09-07
Last Posted Date
2021-06-09
Lead Sponsor
Gilead Sciences
Target Recruit Count
1759
Registration Number
NCT02889796
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy